Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) experienced a slight decline of 0.41%, closing at 4415.21 points on December 10, with a trading volume of 6.972 billion yuan and a turnover rate of 0.9% [1] Group 1: Index Performance - The Shenzhen-Hong Kong Medical Index closed at 4415.21 points, down 0.41% [1] - The index had a trading volume of 6.972 billion yuan and a turnover rate of 0.9% [1] - Among the constituent stocks, 21 companies saw an increase, with Kewei Medical leading at a 4.14% rise, while 36 companies declined, with Xianjian Technology leading the drop at 9.14% [1] Group 2: Capital Flow - The net outflow of main funds from the Shenzhen-Hong Kong Medical Index constituent stocks totaled 382 million yuan [2] - Retail investors contributed a net inflow of 329 million yuan, while speculative funds saw a net inflow of 53.373 million yuan [2] - Detailed capital flow information for the constituent stocks is available in the accompanying table [2]

Group 1 - The core point of the article is that Xianjian Technology (01302) experienced a significant drop in stock price, falling over 10% during trading, and is currently down 8.57% at HKD 1.6, with a trading volume of HKD 127 million [1] - On December 9, Xianjian Technology announced an agreement involving the trustee Futu Trust Co., Ltd., the seller Xianjian Advanced Technology Limited, and the company regarding a share incentive plan [1] - The agreement stipulates that the trustee, at the company's direction, will purchase 230 million shares from the seller, which represents approximately 4.97% of the company's issued share capital [1] Group 2 - The price for the shares to be sold is set at HKD 1.9 per share, with the total consideration amounting to HKD 437 million, to be settled in cash upon completion [1] - The seller is fully owned by the company's executive director, chairman, and CEO, Xie Yuehui [1]

（文章来源：每日经济新闻） 每经AI快讯，先健科技(01302.HK)盘中一度跌超10%，截至发稿，跌8.57%，报1.6港元，成交额1.27亿 港元。 ...

Core Viewpoint - Xianjian Technology (01302) experienced a significant drop in stock price, falling over 10% during trading, with a current decline of 8.57% to HKD 1.6, and a trading volume of HKD 127 million [1] Group 1: Stock Performance - The stock price of Xianjian Technology fell by over 10% during the trading session [1] - As of the report, the stock is down 8.57%, trading at HKD 1.6 [1] - The trading volume reached HKD 127 million [1] Group 2: Share Sale Agreement - On December 9, Xianjian Technology announced an agreement involving the trustee Futu Trust Co., Ltd., the seller Xianjian Advanced Technology Limited, and the company [1] - The agreement pertains to a share reward plan, where the trustee agrees to purchase 230 million shares, funded by the company, and the seller agrees to sell the same amount [1] - The shares to be sold represent approximately 4.97% of the company's issued share capital [1] Group 3: Financial Details - The price for the shares being sold is set at HKD 1.9 per share, with a total consideration of HKD 437 million [1] - The seller is fully owned by the company's executive director, chairman, and CEO, Xie Yuehui [1]

智通财经APP获悉，先健科技(01302)盘中跌超10%，截至发稿，跌8.57%，报1.6港元，成交额1.27亿港 元。 消息面上，12月9日晚，先健科技发布公告称，信托人富途信托有限公司、卖方Xianjian Advanced Technology Limited及公司订立该协议，据此，就股份奖励计划而言，信托人(经公司指示)同意购买(由 公司提供资金)且卖方同意销售2.3亿股股份。卖方同意销售且信托人同意购买2.3亿股股份，占公司已发 行股本约4.97%。 待售股份的代价为每股待售股份1.9港元，应于完成日期以现金结算（由公司提供资金）。待售股份的 总代价为4.37亿港元。卖方由公司执行董事、主席兼首席执行官谢粤辉全资拥有。 ...

先健科技(01302)发布公告，于2025年12月9日，信托人富途信托有限公司、卖方Xianjian Advanced Technology Limited及公司订立该协议，据此，就股份奖励计划而言，信托人(经公司指示)同意购买(由 公司提供资金)且卖方同意销售2.3亿股股份。 ...

智通财经APP讯，先健科技(01302)发布公告，于2025年12月9日，信托人富途信托有限公司、卖方 Xianjian Advanced Technology Limited及公司订立该协议，据此，就股份奖励计划而言，信托人(经公司 指示)同意购买(由公司提供资金)且卖方同意销售2.3亿股股份。 ...

格隆汇12月9日丨先健科技(01302.HK)公告，内容有关采纳股份奖励计划。于2025年12月9日，信托人富 途信托有限公司、卖方Xianjian Advanced Technology Limited及公司订立该协议，据此，就股份奖励计 划而言，信托人(经公司指示)同意购买(由公司提供资金)且卖方同意销售2.3亿股股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） – 1 – 關連交易－ 根據股份獎勵計劃購買股份 茲提述本公司日期為二零二二年三月三日的公佈，內容有關採納股份獎勵計劃。 於二零二五年十二月九日，信託人、賣方及本公司訂立該協議，據此，就股份獎 勵計劃而言，信託人（經本公司指示）同意購買（由本公司提供資金）且賣方同意銷 售230,000,000股股份。 上市規則涵義 於本公佈日期，賣方於694,194,928股股份中擁有權益，佔本公司已發行股本約 14.99%。緊隨該協議完成後（假設本公司已發行股本並無任何變動），賣方將於 464,194,928股股份中擁有權益，佔本公司已發行股本約10.02%。 根據上市規則第14A章，由於賣方為本公司的主要股東，故其為本公司的關連人 士。該交易構成本公司的關連交易。 由於上市規則項下 ...

资金流向方面，深港通医疗（983035）指数成份股当日主力资金净流出合计2.3亿元，游资资金净流入 合计3861.61万元，散户资金净流入合计1.91亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月9日，深港通医疗（983035）指数报收于4432.3点，跌1.49%，成交73.77亿元，换 手率0.99%。当日该指数成份股中，上涨的有7家，麦克奥迪以1.87%的涨幅领涨，下跌的有50家，先健 科技以8.38%的跌幅领跌。 深港通医疗（983035）指数十大成份股详情如下： ...